GSK partners with Clover Biopharmaceuticals to assist with Coronavirus

GSK has recruited China-based Clover Biopharmaceuticals, to help develop its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer). Under the new agreement, GSK says it will provide Clover with its pandemic adjuvant system for further evaluation of S-Trimer in preclinical studies, in hopes that Clover could potentially rapidly scale-up and produce large-quantities of a new coronavirus vaccine.

Continue Reading